Cargando…

Community-Acquired Pneumonia, Bacterial

Detalles Bibliográficos
Autor principal:	File, Thomas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152131/ http://dx.doi.org/10.1016/B978-1-4377-0126-5.00026-4

Ejemplares similares

Community-acquired pneumonia
por: File, Thomas M
Publicado: (2003)

Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern
por: File, Thomas M
Publicado: (2004)

Antimicrobial therapy of community-acquired pneumonia
por: File, Thomas M., et al.
Publicado: (2004)

The Science of Selecting Antimicrobials for Community-Acquired Pneumonia (CAP)
por: File, Thomas M.
Publicado: (2009)

Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials
por: Paukner, Susanne, et al.
Publicado: (2021)

Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
por: File, Thomas M., et al.
Publicado: (2021)

PNEUMONIA | Community Acquired Pneumonia, Bacterial and Other Common Pathogens
por: Niederman, M.S.
Publicado: (2006)

Community-acquired bacterial pneumonia in adults: An update
por: Eshwara, Vandana Kalwaje, et al.
Publicado: (2020)

Viral and bacterial aetiology of community‐acquired pneumonia in adults
por: Huijskens, Elisabeth G. W., et al.
Publicado: (2012)

Approach to Common Bacterial Infections: Community-Acquired Pneumonia
por: Iroh Tam, Pui-Ying
Publicado: (2013)

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2019)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2020)

2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Schranz, Jennifer, et al.
Publicado: (2019)

Impact of bacterial and viral coinfection in community-acquired pneumonia in adults
por: Lim, Yong Kwan, et al.
Publicado: (2019)

664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes
por: Alexander, Elizabeth, et al.
Publicado: (2019)

Inflammatory response in mixed viral-bacterial community-acquired pneumonia
por: Bello, Salvador, et al.
Publicado: (2014)

Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital
por: Poovieng, Jaturon, et al.
Publicado: (2022)

Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia
por: Townsend, Mary L, et al.
Publicado: (2011)

Severe Community-Acquired Pneumonia
por: Sligl, Wendy I., et al.
Publicado: (2013)

Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography
por: Ito, Isao, et al.
Publicado: (2009)

2237. Early Discontinuation of Antibacterials Is Safe for Patients with Community-Acquired Pneumonia (CAP) Who Have a Positive Viral Test, Negative Tests for Bacteria, and Low Procalcitonin
por: Politis, Paula Ann, et al.
Publicado: (2019)

COMMUNITY-ACQUIRED PNEUMONIA
por: Haas, Andrew R., et al.
Publicado: (2009)

Community-Acquired Pneumonia
por: Sialer, Salvador, et al.
Publicado: (2014)

Community Acquired Pneumonia
por: Wunderink, Richard G., et al.
Publicado: (2016)

Community-Acquired Pneumonia
por: Boza Costagliola, María Lina
Publicado: (2020)

Community Acquired Pneumonia
por: Wunderink, Richard G.
Publicado: (2019)

Community-Acquired Pneumonia
por: Rider, Ashley C., et al.
Publicado: (2018)

Community-acquired pneumonia
por: Niederman, Michael S.
Publicado: (2010)

Community-Acquired Pneumonia
por: Wunderink, Richard G.
Publicado: (2017)

Community‐Acquired Pneumonia
Publicado: (2007)

Community-acquired pneumonia
por: Prina, Elena, et al.
Publicado: (2015)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia
por: Maselli, Diego J, et al.
Publicado: (2012)

Community Acquired Pneumonia
por: Finch, Roger
Publicado: (1998)

Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia
por: Adhikary, Shubham, et al.
Publicado: (2022)

Etiology of Community-Acquired Pneumonia
por: Apisarnthanarak, Anucha, et al.
Publicado: (2005)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Epidemiology of community acquired pneumonia
por: Manikam, Logan, et al.
Publicado: (2012)

Community-Acquired Pneumonia in Childhood
por: Popovsky, Erica Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_im378oq8k8n5qne2cjh5bhqdph